Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 16, 2026, 12:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 32,927 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: placebo/placebo Clear all
Completed Phase 3 Interventional Results available

RESPONSE: Response to Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Control to or an Intolerance to Ursodeoxycholic Acid (UDCA)

NCT04620733
View directory record Official record
Conditions
Primary Biliary Cholangitis
Interventions
Seladelpar 10 mg, Placebo, Seladelpar 5 mg
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
193 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
40
States / cities
Chandler, Arizona • Little Rock, Arkansas • Palo Alto, California + 31 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2024 · Synced Sep 16, 2026, 12:14 AM EDT
Completed Phase 2 Interventional Results available

To Assess the Safety and Efficacy of R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca

NCT01900249
View directory record Official record
Conditions
Keratoconjunctivitis Sicca
Interventions
R348 Ophthalmic Solution, 0.2%, R348 Ophthalmic Solution, 0.5%, Placebo
Drug
Lead sponsor
Rigel Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
20
States / cities
Artesia, California • Petaluma, California • Rancho Cardova, California + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2016 · Synced Sep 16, 2026, 12:14 AM EDT
Completed Not applicable Interventional

Study of Glutathione, Vitamin C and Cysteine in Children With Autism and Severe Behavior Problems

NCT00889538
View directory record Official record
Conditions
Autism, Severe Behavior Disorder
Interventions
placebo, glutathione, glutathione, vit C and NAC
Drug
Lead sponsor
University of Louisville
Other
Eligibility
5 Years to 16 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Dec 6, 2016 · Synced Sep 16, 2026, 12:14 AM EDT
Completed Phase 2 Interventional Results available

Study of Pharmacodynamics and Safety of DGAT2i and ACCi Coadministered in Participants With Sponsor-defined Presumed Non Alcoholic Steatohepatitis

NCT04399538
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis, Nonalcoholic Fatty Liver Disease
Interventions
PF-06865571, PF-05221304, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
11
States / cities
Lincoln, California • Montclair, California • Boca Raton, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2023 · Synced Sep 16, 2026, 12:14 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Soy, Bone and Health in College Females

NCT00244478
View directory record Official record
Conditions
Osteoporosis, Obesity
Interventions
Soy Protein Dietary Supplement, Placebo
Dietary Supplement
Lead sponsor
University of Georgia
Other
Eligibility
18 Years to 19 Years · Female only
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Athens, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 24, 2015 · Synced Sep 16, 2026, 12:14 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS

NCT00573443
View directory record Official record
Conditions
Pseudobulbar Affect (PBA)
Interventions
dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg, dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg, Placebo
Drug
Lead sponsor
Avanir Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
326 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
45
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Anaheim, California + 39 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2017 · Synced Sep 16, 2026, 12:14 AM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD) Who Have Had an Inadequate Response to Antidepressants Alone

NCT03738215
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Cariprazine, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
759 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
65
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Rogers, Arkansas + 59 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2022 · Synced Sep 16, 2026, 12:14 AM EDT
Completed Phase 4 Interventional Results available

Trial to Evaluate Beta-Lactam Antimicrobial Therapy of Community Acquired Pneumonia in Children

NCT02891915
View directory record Official record
Conditions
Pneumonia
Interventions
Amoxicillin, Amoxicillin-clavulanate, Cefdinir, Placebo
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Months to 71 Months
Enrollment
385 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
9
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Louisville, Kentucky + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2021 · Synced Sep 16, 2026, 12:14 AM EDT
Completed Phase 2 Interventional

Phase 2b Study to Investigate the Safety and Efficacy of TIN816 in Sepsis-associated Acute Kidney Injury (CLEAR-AKI)

NCT05996835
View directory record Official record
Conditions
Acute Kidney Injury Due to Sepsis
Interventions
TIN816 70 mg lyophilisate powder, Placebo
Biological · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
316 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
19
States / cities
Birmingham, Alabama • San Francisco, California • Stanford, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 16, 2026, 12:14 AM EDT
Withdrawn Not applicable Interventional

Progesterone and Atomoxetine for Cocaine Cessation

NCT01741376
View directory record Official record
Conditions
Cocaine Dependence, Nicotine Dependence
Interventions
Progesterone, Placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 5, 2019 · Synced Sep 16, 2026, 12:14 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Anticipation of Pain Relief on Brain Mechanisms

NCT00200876
View directory record Official record
Conditions
Pain
Interventions
Hypertonic saline, Isotonic saline
Procedure
Lead sponsor
University of Michigan
Other
Eligibility
20 Years to 30 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2008
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 23, 2017 · Synced Sep 16, 2026, 12:14 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Immune Response to Yellow Fever Vaccination in Adults With Atopic Dermatitis

NCT00723489
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Live Yellow Fever Vaccine (YFV-17D), YFV-17D Placebo
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
27 Years to 43 Years
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
3
States / cities
San Diego, California • Denver, Colorado • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 12, 2014 · Synced Sep 16, 2026, 12:14 AM EDT
Recruiting Phase 2 Interventional

Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients

NCT07287189
View directory record Official record
Conditions
Duchenne Muscular Dystrophy, Duchenne, DMD, Neuromuscular Diseases, Muscular Dystrophies
Interventions
SAT-3247, Placebo
Drug
Lead sponsor
Satellos Bioscience, Inc.
Industry
Eligibility
7 Years to 9 Years · Male only
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
7
States / cities
Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Sep 16, 2026, 12:14 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Influence of Short-Term Antibiotic Therapy on Exercise

NCT05961189
View directory record Official record
Conditions
Gastrointestinal Microbiome, Exercise
Interventions
Azithromycin
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 40 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
2
States / cities
Fort Collins, Colorado • New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 16, 2026, 12:14 AM EDT
Completed Phase 1 Interventional Results available

Study to Evaluate Safety and Toxicity of Polyphenon E (EGCG) in HIV-1-Infected Individuals

NCT01433289
View directory record Official record
Conditions
HIV Infection
Interventions
Polyphenon E, Placebo
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 18, 2023 · Synced Sep 16, 2026, 12:14 AM EDT
Terminated Phase 3 Interventional Results available

Effect of Intravenous Corticosteroid Injections on Dysphagia After Cervical Spine Surgery

NCT02266797
View directory record Official record
Conditions
Dysphagia After Anterior Cervical Decompression and Fusion of the Spine
Interventions
Dexamethasone, Saline
Drug · Other
Lead sponsor
NYU Langone Health
Other
Eligibility
21 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
3
States / cities
New York, New York • Westbury, New York
Source: ClinicalTrials.gov public record
Updated Oct 24, 2018 · Synced Sep 16, 2026, 12:14 AM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

Restylane Silk for Treatment of Chest Wrinkles

NCT03324997
View directory record Official record
Conditions
Wrinkle
Interventions
Restylane Silk, Saline, Optical Coherence Tomography
Drug · Device
Lead sponsor
Heidi Waldorf
Other
Eligibility
25 Years to 55 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 5, 2018 · Synced Sep 16, 2026, 12:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Sleep and Healthy Aging Research for Depression (SHARE-D) Study

NCT03256760
View directory record Official record
Conditions
Depression in Old Age
Interventions
Endotoxin, Placebo
Biological
Lead sponsor
Michael Irwin, MD
Other
Eligibility
60 Years to 80 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 4, 2024 · Synced Sep 16, 2026, 12:14 AM EDT
Recruiting Phase 2Phase 3 Interventional

Psilocybin Therapy in Advanced Cancer

NCT05398484
View directory record Official record
Conditions
Advanced Cancer
Interventions
Psilocybin 25 mgs, Niacin 100mg, Psychotherapy
Drug · Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
21 Years to 100 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Aurora, Colorado • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Sep 16, 2026, 12:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety and Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Melrilimab (GSK3772847) in Healthy Participants

NCT04366349
View directory record Official record
Conditions
Healthy Volunteers, Asthma
Interventions
melrilimab (GSK3772847) 70 milligram (mg), melrilimab (GSK3772847) 140 milligram (mg), Placebo
Biological · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Sep 16, 2026, 12:14 AM EDT
Terminated Phase 2 Interventional Results available

A Clinical Study to Test Long Term Safety of GLPG1690 for Patients With Systemic Sclerosis

NCT03976648
View directory record Official record
Conditions
Systemic Sclerosis
Interventions
GLPG1690
Drug
Lead sponsor
Lakefront Biotherapeutics NV
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
6
States / cities
Los Angeles, California • Boca Raton, Florida • Ann Arbor, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2022 · Synced Sep 16, 2026, 12:14 AM EDT
Completed No phase listed Observational

International, Multicenter Study of a Twenty-eight Week, Open-label, Titrated Oral Lixivaptan Administration in Patients With Chronic Hyponatremia: Extension to Studies CK-LX3401, 3405, and 3430

NCT01056848
View directory record Official record
Conditions
Hyponatremia With Normal Extracellular Fluid Volume, Hyponatremia With Excess Extracellular Fluid Volume
Interventions
Not listed
Lead sponsor
CardioKine Inc.
Industry
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
6
States / cities
Lomita, California • Clearewater, Florida • Fleming Island, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2011 · Synced Sep 16, 2026, 12:14 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Effects of a Black Rice Extract and Anthocyanidin Metabolites on the Synthesis and Release of BDNF in Healthy Subjects

NCT06594848
View directory record Official record
Conditions
Cognition - Other, Depression, Anxiety
Interventions
Black rice extract, Placebo
Dietary Supplement · Other
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Sep 16, 2026, 12:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

CAEB071 Thorough QTc Study in Healthy Volunteers

NCT01594255
View directory record Official record
Conditions
Healthy
Interventions
sotrastaurin, placebo to sotrastaurin, Avelox
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 50 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2009
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 8, 2012 · Synced Sep 16, 2026, 12:14 AM EDT